Shares of Immunovant https://www.reuters.com/markets/companies/IMVT.O” target=”_blank” rel=”noopener”>(IMVT.O) more than doubled on Tuesday after early-stage data from its experimental antibody treatment exceeded analysts’ expectations.
Read More
About The Author
